Lupin is planning to set up new state-of-the-art formulation manufacturing facility at the Special Economic Zone (SEZ), MIHAN in Nagpur. The Greenfield plant will take close to a year to being set up.
The company operates 11 world class manufacturing facilities spread across India and Japan. Almost all of Lupin’s facilities have been inspected by leading regulators like the US FDA, UK MHRA, WHO, Australian TGA and Japan’s MHLW.
Lupin has a vibrant presence in the Indian pharmaceuticals market and has over the past several years made major strides in expanding its therapy portfolio. The company has a robust promotion and distribution setup along with a strong presence in various therapeutic areas, including the fast growing diabetes market.
